SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, Honeycomb777, stockinvestor56, jump3mb, Peter Lynch
Search This Board:
Last Post: 12/7/2016 10:41:32 AM - Followers: 100 - Board type: Free - Posts Today: 6

* To access the Replay of 11/10/16 Q3 Conference Call, please dial 1-877-344-7529 Domestically or 1-412-317-0088 Internationally and reference Conference ID: 10096488.
shareholders, please consider purchasing product(s)

***  ALERT ***

Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.


Robert E. Hoffman
Executive Vice President and Chief Financial Officer:

Mr. Hoffman was appointed as our Executive Vice President and Chief Financial Officer on September 6, 2016. Prior to Innovus Pharma, Mr. Hoffman was Chief Financial Officer of AnaptysBio, Inc., a clinical stage biopharmaceutical company. He was part of the founding management team of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), a biopharmaceutical company, in 1997, serving as Senior Vice President, Finance and Chief Financial Officer until 2015. He also served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug company, from March 2011 to August 2011. Mr. Hoffman is a member of the board of directors of CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company, Kura Oncology, Inc. (NASDAQ:KURA), a biotechnology company, and MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX), a biopharmaceutical company. He also was a member of the Financial Accounting Standards Board’s Small Business Advisory Committee until 2015 and is a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman received his B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California.


Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     ~ 106 Million (as of 11/15/16)   Dr. Damaj owns $23.2M shares alone

- Current cash on-hand is enough to fund operations through Q3 of 2017.  Profitability expected at that time !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma

Are you looking to boost your brain health?r


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
INNV News: Amended Statement of Beneficial Ownership (sc 13d/a) 12/05/2016 06:03:26 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 12/02/2016 06:19:20 PM
INNV News: Current Report Filing (8-k) 11/29/2016 06:06:42 AM
INNV News: Securities Registration: Employee Benefit Plan (s-8) 11/28/2016 05:15:33 PM
INNV News: Current Report Filing (8-k) 11/18/2016 04:35:37 PM
#4539  Sticky Note Innovus Pharma Signs $2 Million a Year Exclusive BooDog 11/29/16 06:49:09 AM
#4406  Sticky Note Proven revenue & cash positive potential for 2017. BooDog 11/17/16 06:00:40 AM
#2422  Sticky Note For anyone willing/wondering about how they can HELP Honeycomb777 08/13/16 11:27:51 AM
#4762   the wait will be over very soon.Dont be klimanjaro 12/07/16 11:21:33 AM
#4761   This is not daily trading stock.. JUST BUY TRUMPFORPRES 12/07/16 10:41:31 AM
#4760   what is this nonsense speculation klimanjaro 12/07/16 10:27:09 AM
#4759   Maybe deep pockets had to grease the FDA's Honeycomb777 12/07/16 10:13:36 AM
#4758   ya walmart and walgreens would really get screwed Peter Lynch 12/07/16 09:25:43 AM
#4757   If you're thinking merger blink twice. :-) BooDog 12/07/16 07:11:48 AM
#4756   In addition, let's stop and think about Mr. Honeycomb777 12/06/16 11:25:02 PM
#4755   Another great point/post...this time by Tony over on Yahoo... Honeycomb777 12/06/16 10:56:10 PM
#4754   SH here for 6 months. Waiting on mulally 12/06/16 09:40:25 PM
#4753   One last thought tonight... Honeycomb777 12/06/16 06:54:34 PM
#4752   A recent post from Matthew over on the Honeycomb777 12/06/16 05:29:53 PM
#4751   My sincere apologies ;-) I must confess I s_Henderson 12/06/16 05:07:11 PM
#4750   s_Henderson Tuesday, 12/06/16 12:33:09 PM ShawnP123 12/06/16 03:54:24 PM
#4749   I hope all those frustrated at the PPS, Honeycomb777 12/06/16 03:28:56 PM
#4748   Again you are lying and you didn't read s_Henderson 12/06/16 03:22:03 PM
#4747   If Fluticare is rejected, it will be interesting gi197845 12/06/16 02:46:52 PM
#4746   Again you are lying and you didn't read ShawnP123 12/06/16 01:59:29 PM
#4745   Thanks for passing that on! I totally missed that. BooDog 12/06/16 01:26:26 PM
#4744   So, fundamentals are the key? Then why did s_Henderson 12/06/16 01:16:16 PM
#4743   This is good to know, thanks for sharing! TheBioTechG 12/06/16 01:08:13 PM
#4742   Innovus was happy to give out the shares BooDog 12/06/16 12:59:54 PM
#4741   So, fundamentals are the key? Then why did ShawnP123 12/06/16 12:49:17 PM
#4740   Thank you to "Syd" from Yahoo Finance Boards. s_Henderson 12/06/16 12:46:20 PM
#4739   IB is the best brokerage to short most s_Henderson 12/06/16 12:35:53 PM
#4738   Wow, so it seems like short interest is s_Henderson 12/06/16 12:33:09 PM
#4737   Innv made a deal with Novalere... What is Honeycomb777 12/06/16 12:32:27 PM
#4736   IB is the best brokerage to short most TRUMPFORPRES 12/06/16 12:23:39 PM
#4735   Makes one wonder if a deep pocket is Honeycomb777 12/06/16 12:21:12 PM
#4734   Converning short selling pennystocks, you should all read this: s_Henderson 12/06/16 12:20:16 PM
#4733   My current reasoning for buying INNV is the following: ShawnP123 12/06/16 12:13:46 PM
#4732   Oh you can't p*ss me off by not s_Henderson 12/06/16 12:00:00 PM
#4731   Maybe just to pizzzz yu off ShawnP123 12/06/16 11:57:10 AM
#4730   Brokerage firms have certain requirements for you to s_Henderson 12/06/16 11:49:36 AM
#4729   I am not allowed to short OTC stocks Peter Lynch 12/06/16 10:23:20 AM
#4728   I can't quite understand.. yesterday you wouldn't recommend futurebeaneater 12/06/16 10:19:04 AM
#4727   Why buy all you can now? jump3mb 12/06/16 09:32:09 AM
#4726   I will tell you this, buy all the ShawnP123 12/06/16 09:10:30 AM
#4725   Brokerage firms have certain requirements for you to ShawnP123 12/06/16 09:02:01 AM
#4724   You're so lofty, dude ;-) s_Henderson 12/06/16 08:15:04 AM
#4723   If you knew anything about shorting you should ShawnP123 12/06/16 07:52:27 AM
#4721   Q1 ShawnP123 12/05/16 08:30:54 PM
#4720   I think Honeycomb and ShawnSP are the most Huynh777 12/05/16 08:06:21 PM
#4719   I could see his point IF Mgt was Honeycomb777 12/05/16 06:47:52 PM
#4717   BirdLaw you sound ridiculous. Let me explain why. s_Henderson 12/05/16 06:06:28 PM
#4716   May I ask what the pessimists hope to Honeycomb777 12/05/16 05:44:02 PM
#4715   Henderson, you sound ridiculous. ShawnP has done nothing BirdLaw924 12/05/16 05:26:13 PM
#4713   Ok, I'm going to go with your positive gi197845 12/05/16 04:55:52 PM
#4711   I want his shares so his gone FOREVER! TRUMPFORPRES 12/05/16 04:49:43 PM
#4710   I disagree your opinion about Herbal life... It;s TRUMPFORPRES 12/05/16 04:48:43 PM
#4709   No need to buy Shawns shares, there are gi197845 12/05/16 04:45:56 PM